Remarkable Response to Third-Generation EGFR-TKI Plus Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring EGFR and ROS1 Co-Mutation: a Case Report
FRONTIERS IN ONCOLOGY（2024）
Key words
non-small cell lung cancer,EGFR,ROS1,tyrosine kinase inhibitors,co-mutation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined